Compare KMX & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KMX | PTGX |
|---|---|---|
| Founded | 1993 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.4B |
| IPO Year | 1997 | 2016 |
| Metric | KMX | PTGX |
|---|---|---|
| Price | $48.60 | $82.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 9 |
| Target Price | $40.58 | ★ $93.00 |
| AVG Volume (30 Days) | ★ 4.6M | 863.4K |
| Earning Date | 12-18-2025 | 02-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.67 | N/A |
| EPS | ★ 3.04 | 0.72 |
| Revenue | ★ $27,834,194,000.00 | $209,217,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.99 | $288.98 |
| P/E Ratio | ★ $15.95 | $117.67 |
| Revenue Growth | ★ 0.14 | N/A |
| 52 Week Low | $30.26 | $33.70 |
| 52 Week High | $89.47 | $96.54 |
| Indicator | KMX | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 78.84 | 43.54 |
| Support Level | $44.04 | $78.75 |
| Resistance Level | $48.83 | $87.44 |
| Average True Range (ATR) | 1.71 | 3.01 |
| MACD | 0.83 | -0.27 |
| Stochastic Oscillator | 97.50 | 36.81 |
CarMax sells, finances, and services used and new cars through a chain of over 250 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales were 83% of fiscal 2025 revenue and wholesale about 17%, with the remaining portion composed of extended service plans and repair. In fiscal 2025, the company retailed and wholesaled 789,050 and 544,312 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the US but still estimates that it had only about 3.7% US market share of vehicles 0-10 years old in calendar 2024. It seeks over 5% share. CarMax is based in Richmond, Virginia.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.